Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice.
Shinsuke UchikawaTomokazu KawaokaHiroshi AikataKenichiro KodamaYuno NishidaYuki InagakiMasahiro HatookaKei MorioTakashi NakaharaEisuke MurakamiAkira HiramatsuMasataka TsugeMichio ImamuraYoshiiku KawakamiKazuaki ChayamaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)
Among patients with PD on sorafenib, approximately 30% were eligible for regorafenib treatment, whereas few patients with MVI or hypoalbuminemia at sorafenib initiation were eligible for regorafenib treatment.
Keyphrases